{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T09:28:36Z","timestamp":1780824516825,"version":"3.54.1"},"update-to":[{"DOI":"10.1371\/journal.pntd.0013950","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000}}],"reference-count":46,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/publicdomain\/zero\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"U.S. National Institutes of Health","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001677","name":"INSERM","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100009660","name":"London School of Hygiene and Tropical Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009660","id-type":"DOI","asserted-by":"publisher"}]},{"name":"EDCTP2","award":["RIA2017S-2014"],"award-info":[{"award-number":["RIA2017S-2014"]}]},{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","award":["115854"],"award-info":[{"award-number":["115854"]}],"id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["HHSN261201500003I"],"award-info":[{"award-number":["HHSN261201500003I"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012728","name":"Frederick National Laboratory for Cancer Research","doi-asserted-by":"publisher","award":["HHS0100201700012C"],"award-info":[{"award-number":["HHS0100201700012C"]}],"id":[{"id":"10.13039\/100012728","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosntds.org"],"crossmark-restriction":false},"short-container-title":["PLoS Negl Trop Dis"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Emerging evidence suggests that the time in the day of vaccination may influence post-vaccination immunogenicity. The main objective of this study was to assess the association between the time of vaccination and the anti-EBOV GP\n                      <jats:sub>1,2<\/jats:sub>\n                      IgG antibody response at 12 mo following vaccination against Ebola virus disease (EVD).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methodology\/Principal Findings<\/jats:title>\n                    <jats:p>\n                      This study utilized data from a randomized, double-blind, placebo-controlled international phase 2b clinical trial (PREVAC) evaluating the immunogenicity of three vaccination strategies against Ebola virus disease (rVSV\u0394G-ZEBOV-GP one and two doses, and Ad26.ZEBOV\/MVA-BN-Filo) in 1,859 healthy Western Africans. In the overall population, we measured a statistically significant association between the time of day of first vaccination and anti-Ebola virus immunoglobulin G levels at 12 mo (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.02). The magnitude of this association was small, participants vaccinated at 1600 h were estimated to have 1\u20137% lower antibody levels at 12 mo compared to those vaccinated at 1000 h.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Conclusions\/Significance<\/jats:title>\n                    <jats:p>An effect of the time of first vaccination on the antibody responses was found but remains modest and unlikely to impact the EVD vaccine effectiveness.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Clinical Trials Registration<\/jats:title>\n                    <jats:p>\n                      ClinicalTrials.gov registration:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02876328\" xlink:type=\"simple\">NCT02876328<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pntd.0013950","type":"journal-article","created":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T18:44:42Z","timestamp":1769798682000},"page":"e0013950","update-policy":"https:\/\/doi.org\/10.1371\/journal.pntd.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["Effect of the time of day for vaccination on the immune response to Ebola Virus Disease vaccines: A modeling study from PREVAC randomized trial"],"prefix":"10.1371","volume":"20","author":[{"given":"Ange-Marie D.","family":"Kpetigo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Alexandre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aboubacar","family":"Camara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdoul","family":"Beavogui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seydou","family":"Doumbia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Kieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bailah","family":"Leigh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samba","family":"Sow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Wittkop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Aygline","family":"Soutthiphong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina Maljkovic","family":"Berry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Fleck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Akoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Hamze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Watson-Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens H.","family":"Kuhn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Greenwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Richert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yazdan","family":"Yazdanpanah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"L\u00e9vy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodolphe","family":"Thi\u00e9baut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e9lanie","family":"Prague","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"PREVAC Study Team","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0214-1694","authenticated-orcid":true,"given":"Edouard","family":"Lhomme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,1,30]]},"reference":[{"key":"pntd.0013950.ref001","article-title":"Filovirids: Orthoebolavirus and Orthomarburgvirus infections","volume-title":"Harrison\u2019s Principles of Internal Medicine","author":"JH Kuhn","year":"2026"},{"key":"pntd.0013950.ref002","author":"European Medicines Agency"},{"key":"pntd.0013950.ref003","author":"US Food and Drug Administration","year":"2019"},{"issue":"26","key":"pntd.0013950.ref004","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1056\/NEJMoa2200072","article-title":"Randomized Trial of Vaccines for Zaire Ebola Virus Disease","volume":"387","author":"PREVAC Study Team","year":"2022","journal-title":"N Engl J Med"},{"issue":"15","key":"pntd.0013950.ref005","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1056\/NEJMoa1614067","article-title":"Phase 2 Placebo-Controlled Trial of Two Vaccines to Prevent Ebola in Liberia","volume":"377","author":"SB Kennedy","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"pntd.0013950.ref006","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S1473-3099(21)00125-0","article-title":"Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial","volume":"22","author":"D Ishola","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"pntd.0013950.ref007","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S1473-3099(20)30476-X","article-title":"Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial","volume":"21","author":"AJ Pollard","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"12","key":"pntd.0013950.ref008","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/S1473-3099(17)30541-8","article-title":"Ring vaccination with rVSV-ZEBOV under expanded access in response to an outbreak of Ebola virus disease in Guinea, 2016: an operational and vaccine safety report","volume":"17","author":"P-S Gsell","year":"2017","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"pntd.0013950.ref009","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/s41541-022-00564-z","article-title":"Non-human primate to human immunobridging demonstrates a protective effect of Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola","volume":"7","author":"V Bockstal","year":"2022","journal-title":"NPJ Vaccines"},{"issue":"72","key":"pntd.0013950.ref010","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abm2465","article-title":"The circadian immune system","volume":"7","author":"C Wang","year":"2022","journal-title":"Sci Immunol"},{"issue":"10","key":"pntd.0013950.ref011","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/nri.2016.90","article-title":"Sex differences in immune responses","volume":"16","author":"SL Klein","year":"2016","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"pntd.0013950.ref012","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13293-020-00301-y","article-title":"The impact of sex and gender on immunotherapy outcomes","volume":"11","author":"SL Klein","year":"2020","journal-title":"Biol Sex Differ"},{"key":"pntd.0013950.ref013","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.cell.2014.12.020","article-title":"Variation in the human immune system is largely driven by non-heritable influences","volume":"160","author":"P Brodin","year":"2015","journal-title":"Cell"},{"issue":"2","key":"pntd.0013950.ref014","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00084-18","article-title":"Factors That Influence the Immune Response to Vaccination","volume":"32","author":"P Zimmermann","year":"2019","journal-title":"Clin Microbiol Rev"},{"key":"pntd.0013950.ref015","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1146\/annurev-physiol-021909-135821","article-title":"The mammalian circadian timing system: organization and coordination of central and peripheral clocks","volume":"72","author":"C Dibner","year":"2010","journal-title":"Annu Rev Physiol"},{"key":"pntd.0013950.ref016","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1146\/annurev-neuro-060909-153128","article-title":"Central and peripheral circadian clocks in mammals","volume":"35","author":"JA Mohawk","year":"2012","journal-title":"Annu Rev Neurosci"},{"issue":"1","key":"pntd.0013950.ref017","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/s41467-023-35979-2","article-title":"Influence of circadian clocks on adaptive immunity and vaccination responses","volume":"14","author":"LM Ince","year":"2023","journal-title":"Nat Commun"},{"key":"pntd.0013950.ref018","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1196\/annals.1356.032","article-title":"Modulatory factors of circadian phagocytic activity","volume":"1057","author":"ML Hriscu","year":"2005","journal-title":"Ann N Y Acad Sci"},{"issue":"2","key":"pntd.0013950.ref019","first-page":"225","article-title":"Time is on the Immune System\u2019s Side, Yes it is","volume":"92","author":"SH Abele","year":"2019","journal-title":"Yale J Biol Med"},{"issue":"11","key":"pntd.0013950.ref020","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1038\/s41422-021-00541-6","article-title":"Time of day influences immune response to an inactivated vaccine against SARS-CoV-2","volume":"31","author":"H Zhang","year":"2021","journal-title":"Cell Res"},{"issue":"24","key":"pntd.0013950.ref021","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1016\/j.vaccine.2016.04.032","article-title":"Morning vaccination enhances antibody response over afternoon vaccination: A cluster-randomised trial","volume":"34","author":"JE Long","year":"2016","journal-title":"Vaccine"},{"key":"pntd.0013950.ref022","doi-asserted-by":"crossref","first-page":"5603","DOI":"10.1172\/JCI133934","article-title":"Circadian rhythm influences induction of trained immunity by BCG vaccination","volume":"130","author":"LCJ de Bree","year":"2020","journal-title":"J Clin Invest"},{"issue":"5","key":"pntd.0013950.ref023","doi-asserted-by":"crossref","first-page":"106276","DOI":"10.1016\/j.jinf.2024.106276","article-title":"Time of day for vaccination, outcomes, and relative effectiveness of high-dose vs. standard-dose quadrivalent influenza vaccine: A post hoc analysis of the DANFLU-1 randomized clinical trial","volume":"89","author":"J Christensen","year":"2024","journal-title":"J Infect"},{"issue":"11","key":"pntd.0013950.ref024","doi-asserted-by":"crossref","DOI":"10.1172\/JCI167339","article-title":"Biological rhythms in COVID-19 vaccine effectiveness in an observational cohort study of 1.5 million patients","volume":"133","author":"G Hazan","year":"2023","journal-title":"J Clin Invest"},{"issue":"1","key":"pntd.0013950.ref025","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1177\/07487304221132355","article-title":"The Association of Time of Day of ChAdOx1 nCoV-19 Vaccine Administration With SARS-CoV-2 Anti-Spike IgG Antibody Levels: An Exploratory Observational Study","volume":"38","author":"AC Erber","year":"2023","journal-title":"J Biol Rhythms"},{"issue":"5","key":"pntd.0013950.ref026","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1177\/07487304221100951","article-title":"Time of Day of BNT162b2 COVID-19 Immunization Affects Total SARS-CoV-2 Antibody Levels but Not Neutralizing Activity","volume":"37","author":"F Filippatos","year":"2022","journal-title":"J Biol Rhythms"},{"issue":"1","key":"pntd.0013950.ref027","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1177\/07487304211059315","article-title":"Time of Day of Vaccination Affects SARS-CoV-2 Antibody Responses in an Observational Study of Health Care Workers","volume":"37","author":"W Wang","year":"2022","journal-title":"J Biol Rhythms"},{"issue":"2","key":"pntd.0013950.ref028","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1080\/07420528.2023.2298264","article-title":"Vaccination time does not influence total anti-SARS-CoV-2 antibodies response","volume":"41","author":"L Pighi","year":"2024","journal-title":"Chronobiol Int"},{"issue":"3","key":"pntd.0013950.ref029","doi-asserted-by":"crossref","first-page":"443","DOI":"10.3390\/vaccines10030443","article-title":"The Influence of Time of Day of Vaccination with BNT162b2 on the Adverse Drug Reactions and Efficacy of Humoral Response against SARS-CoV-2 in an Observational Study of Young Adults","volume":"10","author":"P Matryba","year":"2022","journal-title":"Vaccines (Basel)"},{"issue":"11","key":"pntd.0013950.ref030","article-title":"The Impact of Vaccination Time on the Antibody Response to an Inactivated Vaccine against SARS-CoV-2 (IMPROVE-2): A Randomized Controlled Trial","volume":"7","author":"F Lai","year":"2023","journal-title":"Adv Biol (Weinh)"},{"key":"pntd.0013950.ref031","doi-asserted-by":"crossref","first-page":"2432353","DOI":"10.1080\/22221751.2024.2432353","article-title":"Evaluation of waning of IgG antibody responses after rVSV\u0394G-ZEBOV-GP and Ad26.ZEBOV, MVA-BN-Filo Ebola virus disease vaccines: a modelling study from the PREVAC randomized trial","volume":"14","author":"S Valayer","year":"2023","journal-title":"Emerg Microbes Infect"},{"issue":"46","key":"pntd.0013950.ref032","doi-asserted-by":"crossref","first-page":"6599","DOI":"10.1016\/j.vaccine.2022.09.037","article-title":"Immunogenicity of rVSV\u0394G-ZEBOV-GP Ebola vaccine (ERVEBO\u00ae) in African clinical trial participants by age, sex, and baseline GP-ELISA titer: A post hoc analysis of three Phase 2\/3 trials","volume":"40","author":"JK Simon","year":"2022","journal-title":"Vaccine"},{"key":"pntd.0013950.ref033","doi-asserted-by":"crossref","first-page":"104562","DOI":"10.1016\/j.ebiom.2023.104562","article-title":"Immune response of a two-dose heterologous Ebola vaccine regimen: summary of three African clinical trials using a single validated Filovirus Animal Nonclinical Group enzyme-linked immunosorbent assay in a single accredited laboratory","volume":"91","author":"C McLean","year":"2023","journal-title":"EBioMedicine"},{"issue":"1","key":"pntd.0013950.ref034","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/s41541-023-00767-y","article-title":"Prediction of long-term humoral response induced by the two-dose heterologous Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola","volume":"8","author":"M Alexandre","year":"2023","journal-title":"NPJ Vaccines"},{"issue":"1","key":"pntd.0013950.ref035","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13063-021-05035-9","article-title":"Partnership for Research on Ebola VACcination (PREVAC): protocol of a randomized, double-blind, placebo-controlled phase 2 clinical trial evaluating three vaccine strategies against Ebola in healthy volunteers in four West African countries","volume":"22","author":"M Badio","year":"2021","journal-title":"Trials"},{"issue":"4","key":"pntd.0013950.ref036","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0215457","article-title":"Development, qualification, and validation of the Filovirus Animal Nonclinical Group anti-Ebola virus glycoprotein immunoglobulin G enzyme-linked immunosorbent assay for human serum samples","volume":"14","author":"TL Rudge","year":"2019","journal-title":"PLoS One"},{"key":"pntd.0013950.ref037","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1214\/aos\/1013699998","article-title":"The control of the false discovery rate in multiple testing under dependency","volume":"29","author":"Y Benjamini","year":"2001","journal-title":"Ann Stat"},{"key":"pntd.0013950.ref038"},{"issue":"2","key":"pntd.0013950.ref039","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s00281-021-00903-7","article-title":"Circadian rhythms in adaptive immunity and vaccination","volume":"44","author":"N Cermakian","year":"2022","journal-title":"Semin Immunopathol"},{"key":"pntd.0013950.ref040","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1177\/0748730420967768","article-title":"The circadian clock and viral infections","volume":"36","author":"H Borrmann","year":"2021","journal-title":"J Biol Rhythms"},{"key":"pntd.0013950.ref041","doi-asserted-by":"crossref","first-page":"20077","DOI":"10.1073\/pnas.1905080116","article-title":"The circadian clock of CD8 T cells modulates their early response to vaccination and the rhythmicity of related signaling pathways","volume":"116","author":"CC Nobis","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"pntd.0013950.ref042","doi-asserted-by":"crossref","first-page":"100515","DOI":"10.1016\/j.bbih.2022.100515","article-title":"Preliminary evidence that daily light exposure enhances the antibody response to influenza vaccination in patients with dementia","volume":"26","author":"M M\u00fcnch","year":"2022","journal-title":"Brain Behav Immun Health"},{"issue":"3","key":"pntd.0013950.ref043","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1177\/07487304241232447","article-title":"Circadian Variation in the Response to Vaccination: A Systematic Review and Evidence Appraisal","volume":"39","author":"CA Wyse","year":"2024","journal-title":"J Biol Rhythms"},{"issue":"1","key":"pntd.0013950.ref044","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12979-022-00304-w","article-title":"The impact of circadian rhythms on the immune response to influenza vaccination in middle-aged and older adults (IMPROVE): a randomised controlled trial","volume":"19","author":"Y Liu","year":"2022","journal-title":"Immun Ageing"},{"issue":"1","key":"pntd.0013950.ref045","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41576-022-00519-z","article-title":"Genetics of circadian rhythms and sleep in human health and disease","volume":"24","author":"JM Lane","year":"2023","journal-title":"Nat Rev Genet"},{"issue":"18","key":"pntd.0013950.ref046","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00579-19","article-title":"Dynamics of the Humoral Immune Response to a Prime-Boost Ebola Vaccine: Quantification and Sources of Variation","volume":"93","author":"C Pasin","year":"2019","journal-title":"J Virol"}],"updated-by":[{"DOI":"10.1371\/journal.pntd.0013950","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000}}],"container-title":["PLOS Neglected Tropical Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0013950","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T18:48:38Z","timestamp":1770835718000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0013950"}},"subtitle":[],"editor":[{"given":"Anne W.","family":"Rimoin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,1,30]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,30]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pntd.0013950","relation":{},"ISSN":["1935-2735"],"issn-type":[{"value":"1935-2735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,30]]}}}